GC-1118A is under clinical development by GC Biopharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GC-1118A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-1118A is under development for the treatment of gastric cancer, colon cancer and gastroesophageal junction adenocarcinoma. It is a fully human monoclonal antibody administered through intravenous route. The drug candidate acts by targeting EGFR.
It was also under development for the treatment of head and neck cancer, lung cancer, metastatic colorectal cancer, advanced solid tumor and glioblastoma multiforme.
GC Biopharma overview
GC Biopharma, formerly known as GC Pharma, a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products, and others. The company focuses its research and development activities on developing drugs for treatment of cancer, tuberculosis, and hunter syndrome, among others. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.
For a complete picture of GC-1118A’s drug-specific PTSR and LoA scores, buy the report here.